Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc. engages in the provision of designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with human papillomavirus. Its product pipeline includes VGX-3100, INO-3107, INO-5410, INO-4800, and PENNVAX-GP. The company was founded by David B. Weiner on June 29, 1983 and is headquartered in Plymouth Meeting, PA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Inovio progresses on RRP treatment, faces trial challenges and opportunities

Inovio Pharmaceuticals is making progress on INO-3107 and other pipeline candidates while managing financials and strategic trial design.
The company faces challenges in trial design, patient representation, and regulatory requirements but sees opportunities in market access and patient outcomes.
Overall, Inovio remains focused on advancing DNA medicine and delivering on key objectives for the benefit of patients.
Analysts' questions and executive responses indicate a thorough approach to addressing concerns and ensuring trial success.

INOVIO Pharmaceuticals reports solid Q3 performance and eyes global expansion

INOVIO Pharmaceuticals showcased financial stability, regulatory progress, and scientific advancements in Q3 2024, positioning the company for future growth.
Despite financial challenges and potential hurdles, the company's strong financial position, robust pipeline, and strategic commercial planning offer opportunities for success.
Addressing challenges like financial losses, regulatory complexities, and market competitiveness will be crucial for maximizing opportunities and achieving long-term growth.
By leveraging strengths, navigating challenges, and capitalizing on opportunities, INOVIO Pharmaceuticals aims to drive innovation, secure regulatory approvals, and capture market share.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Inovio Pharmaceuticals (INO) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to loss of $0.36 per share a year ago.

Inovio Pharmaceuticals (INO) Reports Q1 Loss, Misses Revenue Estimates

Announced additional positive data from Phase 1/2 trial for INO-3107 in recurrent respiratory papillomatosis patients Second cohort of trial showed 10 of the 11 (91%) patients saw a reduction in surgical interventions in the year following initial treatment New combined safety and immunological data showing tolerability and durable immune response presented at ABEA/COSM Announced positive data from Phase 1b trial with INO-4201 as an Ebola booster for ERVEBO® INO-4201 was well-tolerated and boosted humoral responses in 36 of 36 (100%) treated participants New safety and immunological data indicating potential to extend protection against Ebola presented at ECCMID Announced topline results for REVEAL2, the second Phase 3 trial for VGX-3100 as a treatment for cervical high-grade squamous intraepithelial lesions Analysis of clinical characteristics of biomarker population is ongoing; findings to be shared in third quarter 2023 Trial results achieved statistical significance in all-participants population Trial results did not meet primary endpoint in biomarker-selected population Enhanced product development team with appointment of Dr. Cheryl Elder as Senior Vice President, Regulatory Affairs Ended the first quarter 2023 with $223.8 million in cash, cash equivalents and short-term investments Company maintains cash runway projection into first quarter 2025 Management will host conference call today at 4:30 p.m. EDT PLYMOUTH MEETING, Pa.

INOVIO Reports First Quarter 2023 Financial Results and Operational Highlights

Oral presentation provided new combined safety and immunogenicity data from both cohorts (standard and side-port needles) Data indicates INO-3107 was well tolerated and has the potential to provide clinical benefit to adults with RRP PLYMOUTH MEETING, Pa. , May 8, 2023 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, presented new data from a Phase 1/2 trial of INO-3107 (NCT:04398433) for the treatment of HPV 6 and HPV 11-associated Recurrent Respiratory Papillomatosis (RRP) on May 5 th as part of the scientific program of the American Broncho-Esophagological Association (ABEA) at the Combined Otolaryngology Spring Meetings (COSM) in Boston, Massachusetts.

New Data from Phase 1/2 Trial of INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis Presented at ABEA during COSM 2023

PLYMOUTH MEETING, Pa. , May 5, 2023 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that Jacqueline Shea, Ph.D.

INOVIO to Present at the 2023 RBC Capital Markets Global Healthcare Conference

PLYMOUTH MEETING, Pa. , April 28, 2023 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer, and infectious diseases, today announced that first quarter 2023 financial results will be released after the market close on May 10, 2023.

INOVIO to Report First Quarter 2023 Financial Results on May 10, 2023

Safety and Immunological data from both cohorts of the recently completed Phase 1/2 trial will be presented on May 5 th PLYMOUTH MEETING, Pa. , April 27, 2023 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer, and infectious diseases, today announced that an abstract has been accepted for oral presentation on INO-3107 for the treatment of Recurrent Respiratory Papillomatosis (RRP) at this year's American Broncho-Esophagological Association (ABEA) program at the Combined Otolaryngology Spring Meetings (COSM) in Boston, Massachusetts.

INOVIO Announces Acceptance of Abstract for Oral Presentation on INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis at COSM 2023

European Commission to review and make a final decision, expected late May 2023 PLYMOUTH MEETING, Pa. , April 26, 2023 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that the European Committee for Orphan Medicinal Products (COMP) has provided a positive opinion on INOVIO's application for orphan drug designation in the European Union (EU) for INO-3107.

European Committee for Orphan Medicinal Products Provides Positive Opinion on INOVIO's Application for Orphan Drug Designation for INO-3107

Bright Minds Biosciences

Genprex

Heliogen

mCloud Technologies Corp

National CineMedia

NeuroBo Pharmaceuticals Inc

Oncternal Therapeutics Inc

Predictive Oncology Inc

Vascular Biogenics

Penny stocks under $1 to watch this week. The post Penny Stocks To Buy?

Penny Stocks To Buy? 10 Under $1 To Watch This Week

Agenus

Roivant Sciences Ltd

Merck's decision to pay top dollar for a late-stage asset is sparking a wave of bargain buying in biotech today. Agenus, Inovio Pharmaceuticals, and Roivant Sciences are three of the biggest beneficiaries of the industrywide trend.

These 3 Nasdaq Stocks Are on Fire Today: Here's Why

Penny stocks to watch trading for pennies this week. The post Penny Stocks To Buy?

Penny Stocks To Buy? 7 Under $1 To Watch This Week

Inovio's shares are down more than 43% this year. The company said it has enough cash to last into the first quarter of 2025.

Why Inovio Pharmaceuticals' Shares Jumped on Thursday

Altimmune

Ardelyx

Cidara Therapeutics

FaZe Holdings Inc

ImmunityBio

Olaplex Holdings

RLX Technology

Silvergate Capital Corp

Tupperware

10 Penny stocks under $5 to watch right now The post Top Penny Stocks To Buy Now? 10 To Watch Under $5 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Top Penny Stocks To Buy Now? 10 To Watch Under $5

PLYMOUTH MEETING, Pa., April 12, 2023 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer, and infectious diseases, today announced that an abstract has been accepted for presentation for INO-4201 as an Ebola booster for rVSV-ZEBOV (Ervebo) at the 33rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID).

INOVIO Announces Acceptance of Abstract for Oral Presentation on INO-4201 as an Ebola Booster for rVSV-ZEBOV (Ervebo®) at ECCMID 2023

Inovio said it has enough cash to fund operations into the first quarter of 2025. The company focuses on DNA medicines to treat HPV diseases, cancer, and infectious diseases.

Why Shares of Inovio Pharmaceuticals Were Down Tuesday

The company focuses on investing in office properties in France, Germany, and Spain, and it had a book value per unit of C$9.58 ($7.00) as of September. There are some issues with vacancy rates, and I expect the dividend to be cut in the near future, but Inovalis is in a good position for a challenging 2023.

Inovalis: Small Office REIT With A Double-Digit Dividend Yield

Inovio Pharmaceuticals, Inc. (NASDAQ:INO ) Oppenheimer 33rd Annual Healthcare Conference Call March 13, 2023 10:40 AM ET Company Participants Jacqueline Shea - President and Chief Executive Officer Conference Call Participants Hartaj Singh - Oppenheimer Hartaj Singh Great, thank you. Thanks always to the operators for making this so easy.

Inovio Pharmaceuticals, Inc. (INO) Oppenheimer 33rd Annual Healthcare Conference (Transcript)

PLYMOUTH MEETING, Pa. , March 3, 2023 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that Jacqueline Shea, Ph.D.

INOVIO to Present at the Oppenheimer 33rd Annual Healthcare Conference

Inovio Pharmaceuticals, Inc. (NASDAQ:INO ) Q4 2022 Earnings Conference Call March 1, 2023 4:30 PM ET Company Participants Thomas Hong - Manager-Investor Communications Jacqueline Shea - President and Chief Executive Officer Michael Sumner - Chief Medical Officer Peter Kies - Chief Financial Officer Conference Call Participants Hartaj Singh - Oppenheimer Charlie Young - Bank of America Yi Chen - H.C. Wainwright Operator Good afternoon, and welcome to the Inovio Pharmaceuticals Fourth Quarter 2022 Financial Results Conference Call.

Inovio Pharmaceuticals, Inc. (INO) Q4 2022 Earnings Call Transcript

Inovio (INO) delivered earnings and revenue surprises of -31.25% and 72.59%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Inovio Pharmaceuticals (INO) Reports Q4 Loss, Lags Revenue Estimates

Announces topline results from REVEAL2, the second Phase 3 trial evaluating VGX-3100 as a treatment for cervical high-grade squamous intraepithelial lesions (HSIL) Trial results did not meet the primary endpoint in the biomarker-selected population Trial results did achieve statistical significance in the all-participants population Highlights progress of promising product candidates: Positive preliminary data from Phase 1/2 trial of INO-3107 for the treatment of Recurrent Respiratory Papillomatosis Positive Phase 1b data for INO-4201 as Ebola booster for Ervebo® as primary series Positive data from a Phase 1/2 trial with INO-5401 in patients with glioblastoma Updated results published for INO-3112, a product candidate being evaluated for the treatment of HPV-related cancers Ended 2022 with $253 million in cash, cash equivalents, and short-term investments and maintains cash runway projections to first quarter 2025 Management will host conference call today at 4:30 p.m. ET PLYMOUTH MEETING, Pa.

INOVIO Reports Fourth Quarter and Full Year 2022 Financial Results and Clinical Highlights

Novavax

Both stocks soared during the coronavirus vaccine race, but their time has passed.

2 Stocks to Sell or Remove From Your Watchlist in 2023

10 of 11 patients (91%) had a reduction in number of surgical interventions, measured from Day 0 to one year following initial treatment; 4 of the 10 patients did not need any surgery Treatment with INO-3107 achieved statistical significance based on clinical endpoint of reduction in overall number of surgical interventions compared with previous year INO-3107 was well-tolerated and immunogenic, with efficacy and safety results for second cohort consistent with first cohort Patients in second cohort were administered INO-3107 using the exploratory side port needle PLYMOUTH MEETING, Pa. , Feb. 16, 2023 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer, and infectious diseases, today announced positive preliminary results from the second cohort of its Phase 1/2 clinical trial evaluating INO-3107 for the treatment of HPV 6 and HPV 11-associated Recurrent Respiratory Papillomatosis (RRP) in adults.

INOVIO Announces Positive Preliminary Results from Second Cohort of Phase 1/2 Trial with INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis

PLYMOUTH MEETING, Pa. , Feb. 15, 2023 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer, and infectious diseases, today announced that fourth quarter 2022 financial results will be released after the market close on March 1, 2023.

INOVIO to Report Fourth Quarter and Year-End 2022 Financial Results on March 1, 2023

Crown ElectroKinetics

PaxMedica Inc

Should penny stocks be on your watchlist? The post Are Penny Stocks on Your February Watchlist?

Are Penny Stocks on Your February Watchlist? 3 Reasons to Buy

INO-4201 found to be well-tolerated in the trial Humoral responses were boosted in 100% (36 of 36) of treated participants PLYMOUTH MEETING, Pa. , Feb. 2, 2023 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer, and infectious diseases, today announced positive results from a Phase 1b clinical trial evaluating INO-4201, a DNA vaccine candidate, as a booster in healthy adult participants who previously received a single injection of Ervebo.

INOVIO Reports Positive Phase 1b Results for INO-4201 as an Ebola Booster for rVSV-ZEBOV (Ervebo®)

News for Inovio Pharmaceuticals Stock (INO)